Position of the Transparency Council – Synacthen, Synacthen Depot (tetracosactide)
At its meeting on 9 June 2025, the Transparency Council adopted position No. 72/2025 on the validity of granting approvals for the reimbursement of medicinal products Synacthen, Synacthen Depot (tetracosactide) for the following indications: drug-resistant epilepsy, drug-resistant epilepsy in the form of West syndrome, drug-resistant epilepsy in the form of Lennox-Gastaut syndrome, Kinsbourne syndrome, Landau-Kleffner syndrome.